Animal Models for Studying Drug Metabolizing Enzymes and Transporters

ADME-Enabling Technologies in Drug Design and Development

Volumn , Issue , 2012, Pages 253-276

  Salyers, Kevin L ^a   Xu, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Animal models, and role of key DMEs, cytochrome P450 s; DMEs in human drug metabolism and toxicity, and DME regulation; Drug metabolizing enzymes and transporters, and animal models; in vivo models, role of DMEs in determining oral bioavailability; Transporter mediated DDI prediction, transporters characterized

Indexed keywords

EID: 84886215902     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118180778.ch16     Document Type: Chapter

References (132)

1. Abaut A-Y, Chevanne F, Corre PL (2007) Oral bioavailability and intestinal secretion of amitriptyline: Role of P-glycoprotein? International Journal of Pharmaceutics 330: 121-128.
2. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. The Journal of Biological chemistry 274: 17159-17163.
3. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki M, Numoki K, Sato E, Seki M, Date F, Ono K, Kondo Y, Shiba K, Suzuki M, Ohtani H, Shimosegawa T, Linuma K, Nagura H, Ito S, Matsun S (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120: 1689-1699.
4. Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y (2005) Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Molecular Pharmacology 67: 923-928.
5. Adler ID, Baumgartner A, Gonda H, Friedman MA, Skerhut M (2000) 1-Aminobenzotriazole inhibits acrylamide-induced dominant lethal effects in spermatids of male mice. Mutagenesis 15: 133-136.
6. Aitken AE, Richardson TA, Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. A nnual Review of Pharmacology and Toxicology 46: 123-149.
7. Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical Pharmacology and Therapeutics 59: 7-13.
8. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW (2002) Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metabolism and Disposition 30: 1059-1062.
9. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131-1152.
10. Bohets H, Annaert P, Mannens G, Van BL, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K (2001) Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 1: 367-383.
11. Breedveld P, Pluim D, Cipriani G, Weilinga P, van Tellingen O, Schinkel AH, Schellens HM (2005) The effect of Bcrp (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Research 65: 2577-2582.
12. Bullock P, Pearce R, Draper A, Podval J, Bracken W, Veltman J, Thomas P, Parkinson A (1995) Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metabolism and Disposition 23: 736-748.
13. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Cotto C, Hall J, Hasting B, Jones W (2005) The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens. European Journal of Drug Metabolism and Pharmacokinetics 30: 75-83.
14. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: Species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metabolism and Disposition 34: 1703-1712.
15. Chen C, Hanson E, Watson JW, Lee JS (2003a) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonist. D rug Metabolism and Disposition 31: 312-318.
16. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X (2003b) Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharmaceutical Research 20: 31-37.
17. Cheung C, Gonzalez FJ (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. The Journal of Pharmacology and Experimental Therapeutics 327: 288-299.
18. Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ (2006) Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. The Journal of Pharmacology and Experimental Therapeutics 316: 1328-1334.
19. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into the brain and testes. Drug Metabolism and Disposition 28: 655-660.
20. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ (2001) The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Molecular Pharmacology 60: 1260-1267. [Erratum appears in Molecular Pharmacology 2002;61(1):248].
21. Cordon-Cardo C, O' Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences of the United States of America 86: 695-698.
22. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE (1989) The three mouse multidrug resistance (mdr1) genes are expressed in a tissue specific manner in normal mouse tissue. Molecular and Cellular Biology 9: 1346-1350.
23. DeKeyser JG, Shou M (2011) Species differences of drug metabolizing enzymes. In Encyclopedia of Drug Metabolism, Vol. 1. Sinz M, Rodrigues D, eds. John Wiley & Sons, Hoboken, NJ. (In press).
24. Dietrich CG, Rudi de Waart D, Ottenhoff R, Scoots IG, Oude Elerink RP (2001) Increased bioavailability of the food -derived carcinogen 2-amino-1-methy-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Molecular Pharmacology 59: 974-980.
25. Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ (2001) Interactions between cimetidine, nitrofurantoin and probenecid active transport into rat milk. The Journal of Pharmacology and Experimental Therapeutics 296: 175-180.
26. Gonzalez FJ, Yu AM (2006) Cytochrome P450 and xenobiotic receptor humanized mice. Annual Review of Pharmacology and Toxicology 46: 41-64.
27. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: In vitro metabolism and pharmacokinetics of midazolam. D rug Metabolism and Disposition 31: 548-558.
28. Guengerich FP (1997) Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions 106: 161-182.
29. Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W (2003) Cytochrome P450 3A4 activity after surgical stress. Critical Care Medicine 31: 1338-1346.
30. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Molecular and Cellular Biology 21: 1393-1403.
31. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, Vaalburg W, Franssen EJ (1999) A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Research 59: 2411-2416.
32. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. T he Journal of Clinical Investigation 117: 3583-3592.
33. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Molecular Pharmacology 68: 800-807.
34. Hoffman DJ, Seifert T, Borre A, Nellans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharmaceutical Research 12: 889-894.
35. Iwasaki K, Uno Y (2009) Cynomolgus monkey CYPs: A comparison with human CYPs. Xenobiotica 39: 578-581.
36. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Bijen JH, Schellens JHM, Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 92: 1651-1656.
37. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1] gene. Molecular and Cellular Biology 21: 5471-5477.
38. Kacevska M, Robertson GR, Clarke SJ, Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: Impact and implications for chemotherapeutic drug dosing. Expert Opinion On Drug Metabolism and Toxicology 4: 137-149.
39. Kaddoumi A, Choi S, Kinman L, Whittington D, Tsai C-C, Ho RJ, Anderson BD, Unadkat JD (2007) Inhibition of P-gp activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the CSF. Drug Metabolism and Disposition 35: 1459-1462.
40. Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M (2004a) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34: 391-402.
41. Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M (2004b) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: Establishment and evaluation of dexamethasone-pretreated female rats. Xenobiotica 34: 403-413.
42. Kanazu T, Okamura N, Yamaguchi Y, Baba T, Koike M (2005) Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 35: 305-317.
43. Katoh M, Yokoi T (2007) Application of chimeric mice with humanized liver for predictive ADME. Drug Metabolism Reviews 39: 145-157.
44. Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T (2005) In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metabolism and Disposition 33: 754-763.
45. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. The Journal of Clinical Investigation 101: 289-294.
46. Kim S, Dinchuk JE, Anthony MN, Orcutt T, Zoeckler ME, Sauer MB, Mosure KW, Vuppugalla R, Grace JE Jr., Simmermacher J, Dulac HA, Pizzano J, Sinz M (2010) Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metabolism and Disposition 38: 16-24.
47. Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490.
48. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ (2002) In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. The Journal of Pharmacology and Experimental Therapeutics 302: 1228-1237.
49. Kunta JR, Lee SH, Perry BA, Lee YH, Sinko PJ (2004) Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metabolism and Disposition 32: 1293-1298.
50. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. Journal of the American Society of Nephrology 12: 326-332.
51. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, Suhara T (2006) In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using 11 C-verapamil. The Journal of Pharmacology and Experimental Therapeutics 316: 647-653.
52. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF (2006) Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Research 66: 4802-4807.
53. Liang HC, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, Nebert DW (1996) Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proceedings of the National Academy of Sciences of the United States of America 93: 1671-1676.
54. Lin LA, Shangari N, Chan TS, Remirez D, O' Brien PJ (2006) Herbal monoterpene alcohols inhibit propofol metabolism and prolong anesthesia time. Life Sciences 79: 21-29.
55. Liu H, Baliga R (2003) Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney International 63: 1687-1696.
56. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ (2007) Rifaximin is a gut-specific human pregnane X receptor activator. The Journal of Pharmacology and Experimental Therapeutics 322: 391-398.
57. Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ (2008) A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metabolism and Disposition 36: 2506-2512.
58. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296: 1313-1316.
59. Mandlekar SV, Rose AV, Cornelius G, Sleczka B, Caporuscio C, Wang J, Marathe PH (2007) Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica 37: 923-942.
60. Marathe PH, Rodrigues AD (2006) In vivo animal models for investigating potential CYP3A-and Pgp-mediated drug-drug interactions. Current Drug Metabolism 7: 687-704.
61. Martignoni M, Groothuis GM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion On Drug Metabolism and Toxicology 2: 875-894.
62. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD (2006) Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: The role of CYP3A and P-glycoprotein. The Journal of Pharmacology and Experimental Therapeutics 316: 1202-1209.
63. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. M olecular Pharmacology 67: 1758-1764.
64. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metabolism and Disposition 32: 898-901.
65. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition 36: 205-216.
66. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, Ogihara T (2008) Oseltamer (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metabolism and Disposition 36: 6-9.
67. Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W (2006) Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. The Journal of Pharmacology and Experimental Therapeutics 316: 1369-1377.
68. Muruganandan S, Sinal CJ (2008) Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. C linical Pharmacology and Therapeutics 83: 818-828.
69. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and highfield NMR: Species differences in the metabolism of efavirenz. Drug Metabolism and Disposition 27: 1319-1333.
70. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT (2000) The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicology and Applied Pharmacology 169: 102-113.
71. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
72. Nelson SD, Slattery JT, Thummel KE, Watkins PB (2003) Car unlikely to significantly modulate acetaminophen hepatotoxicity in most humans. Hepatology 38: 254-257.
73. Nolin TD, Naud J, Leblond FA, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clinical Pharmacology and Therapeutics 83: 898-903.
74. Ogasawara A, Kume T, Kazama E (2007) Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metabolism and Disposition 35: 410-418.
75. Oostendorp RL, Buckle T, Beijnen JH, Tellingen OV, Schellens JH (2009) The effect of P-gp (Mdr1a/b) BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational New Drugs 27: 31-40.
76. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of osteltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and mulidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metabolism and Disposition 37: 315-321.
77. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics 60: 14-24.
78. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D (2001) Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America 98: 7498-7503.
79. Perloff MD, Von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms. The Journal of Pharmacology and Experimental Therapeutics 292: 618-628.
80. Peterson TC, Peterson MR, Wornell PA, Blanchard MG, Gonzalez FJ (2004) Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochemical Pharmacology 68: 395-402.
81. Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: A preclinical approach for CYP3A-mediated drug interaction studies. Drug Metabolism and Disposition 34: 1546-1555.
82. Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Current Drug Metabolism 5: 235-243.
83. Robertson GR, Liddle C, Clarke SJ (2008) Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clinical Pharmacology and Therapeutics 83: 894-897.
84. Rowland M, Tozer TN (1995) Clinical Pharamcokinetics: Concepts and Application. Lippincott Williams & Wilkins, Philadelphia.
85. Salyers KL (2009) Preclinical pharmacokinetic models for drug discovery and development. In Handbook of Drug Metabolism, 2nd ed., Pearson PG, Wienkers LC, eds., pp. 659-673. Informa Healthcare, New York.
86. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics 77: 503-514.
87. Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD (2002) Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metabolism and Disposition 30: 479-482.
88. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJ, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
89. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A. The Journal of Clinical Investigation 96: 1698-1705.
90. Schinkel AH, Wagenaar E, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of Clinical Investigation 97: 2517-2524.
91. Schinkel AH, Mayer U, Wagenaar E (1997) Normal and altered pharmacokinetics in mice lacking Mdr1-type (drug transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 94: 4028-4033.
92. Shitara Y, Horie T, Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences 27: 425-446.
93. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. The Journal of Biological Chemistry 275: 40504-40510.
94. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. British Journal of Clinical Pharmacology 23: 545-551.
95. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Pharmacology 94: 2031-2035.
96. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proceedings of the National Academy of Sciences of the United States of America 98: 3369-3374.
97. van de Steeg E, van Der Kruijssen CM, Wagenarr E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH (2009) Methotreate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCo1B1). Drug Metabolism and Disposition 37: 277-281.
98. Strelevitz TJ, Foti RS, Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. Journal of Pharmaceutical Sciences 95: 1334-1341.
99. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, Gerebtoff G, Lennernaes H, Senner F (2010) Coexistence of passive and carrier-mediated processes in drug transport. Nature reviews. Drug discovery 9: 597-614.
100. Tahara H, Kusuhara H, Fuse E, Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metabolism and Disposition 33: 963-968.
101. Takano M, Yumoto R, Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacology and Therapeutics 109: 137-161.
102. Tam-Zaman N, Tam YK, Tawfik S, Wiltshire H (2004) Factors responsible for the variability of saquinavir absorption: Studies using an instrumented dog model. Pharmaceutical Research 21: 436-442.
103. Tang W, Stearns RA, Wang RW, Miller RR, Chen Q, Ngui J, Bakshi RK, Nargund RP, Dean DC, Baillie TA (2008) Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: A case study with melanocortin-4 receptor agonists. Xenobiotica 38: 1437-1451.
104. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. The American Journal of Pathology 165: 901-912.
105. Thummel KE, O' Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. C linical Pharmacology and Therapeutics 59: 491-502.
106. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J, Schuetz E (2001) Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Molecular Pharmacology 60: 1399-1406.
107. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics 66: 461-471.
108. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 37: 1367-1377.
109. Uppal H, Toma D, Saini SP, Ren S, Jones TJ, Xie W (2005) Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41: 168-176.
110. Von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ (2004) Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metabolism and Disposition 32: 800-804.
111. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissues distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 13: 129-134.
112. Wang D, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. The Journal of Pharmacology and Experimental Therapeutics 302: 510-515.
113. Wang H, Xie W (2009) Nuclear receptor-mediated gene regulation in drug metabolism. In Drug Metabolism Handbook: Concepts and Applications, Nassar AF, Hollenberg PF, Scatina J, eds., pp. 449-478. John Wiley & Sons, Hoboken, NJ.
114. Wang SW, Kulkarni KH, Tang L, Wang JR, Yin T, Daidoji T, Yokota H, Hu M (2009) Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. The Journal of Pharmacology and Experimental Therapeutics 329: 1023-1031.
115. Ward KW, Azzarano LM (2004) Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF 120918A (HCl salt of GF 120918, 9, 10-dihydro-5-methoxy9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) ethyl] phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. The Journal of Pharmacology and Experimental Therapeutics 310: 703-709.
116. Ward KW, Proksch JW, Levy MA, Smith BR (2001) Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metabolism and Disposition 29: 82-88.
117. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, Surdy-Freed JE, Proksch JW, Smith BR (2004) Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metabolism and Disposition 32: 172-177.
118. Watanabe T, Furukawa T, Sharyo S, Ohashi Y, Yasuda M, Takaoka M, Manabe S (2000) Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. The Journal of Toxicological Sciences 25: 423-431.
119. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Molecular Pharmacology 73: 1029-1036.
120. Watkins JB, Klaassen CD (1983) Chemically-induced alteration of UPD-glucuronic acid concentration in rat liver. Drug Metabolism and Disposition 11: 37-40.
121. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clinical Pharmacology and Therapeutics 58: 492-497.
122. WuDunn D (2002) Genetic basis of glaucoma. Current Opinion in Ophthalmology 13: 55-60.
123. Xia CQ, Yang JJ, Balani S (2008) Drug transporters in drug disposition, drug interactions, and drug resistance. In Drug Metabolism in Drug Design and Development, Zhang D, Zhu M, Humphreys WG, eds., pp. 137-202. John Wiley & Sons, Hoboken, NJ.
124. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406: 435-439.
125. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proceedings of the National Academy of Sciences of the United States of America 98: 3375-3380.
126. Xu Y, Iwanaga K, Zhou C, Cheesman MJ, Farin F, Thummel KE (2006) Selective induction of intestinal CYP3A23 by 1alpha,25-dihydroxyvitamin D3 in rats. Biochemical Pharmacology 72: 385-392.
127. Yao C, Levy RH (2002) Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data. Journal of Pharmaceutical Sciences 91: 1923-1935.
128. You G, Morris ME (2007) Overview of drug transporter families. In Drug Transporters: Molecular Characterization and Role in Drug Disposition. You G, Morris ME, eds., pp. 1-10. John Wiley & Sons, Hoboken, NJ.
129. Yu AM, Idle JR, Gonzalez FJ (2004) Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metabolism Reviews 36: 243-277.
130. Zhang H, Zhang D, Li W, Yao M, D' Arienzo C, Li YX, Ewing WR, Gu Z, Zhu Y, Murugesan N, Shyu WC, Humphreys WG (2007) Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metabolism and Disposition 35: 795-805.
131. Zhang H, Wu X, Chung F, Naraharisetti SB, Whittington D, Mirfazaelian A, Unadkat JD (2009) As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina. The Journal of Pharmacology and Experimental Therapeutics 329: 1016-1022.
132. Zhang J, Huang W, Chua SS, Wei P, Moore DD (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298: 422-424.